Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

Summary

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Schizophrenia
• Bipolar Disorder
• Autism Spectrum Disorder

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

5 to 17 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Intra-Cellular Therapies, Inc.

Last updated on ClinicalTrials.gov

September 25, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites